Inspira Technologies Oxy B.H.N. Ltd. Warrant - IINNW STOCK NEWS

Welcome to our dedicated page for Inspira Technologies Oxy B.H.N. Ltd. Warrant news (Ticker: IINNW), a resource for investors and traders seeking the latest updates and insights on Inspira Technologies Oxy B.H.N. Ltd. Warrant stock.

Inspira Technologies Oxy BHN Ltd is a specialty medical device company focused on developing innovative respiratory support technology as an alternative to mechanical ventilation. By 2020, over 600,000 patients in the U.S. will need mechanical ventilation, with a significant portion requiring ICU admission, costing an estimated $64 billion annually. The company's OxyLink technology, an advanced nano vesicle device, introduces an intravascular oxygenation system to enhance blood oxygen levels and reduce carbon dioxide, enabling physicians to address primary ventilatory conditions effectively.

The company has recently received 510(k) class II clearance from the U.S. FDA for its INSPIRA ART100 Cardiopulmonary Bypass System. Inspira Technologies aims to revolutionize the respiratory care market with its innovative products, including the INSPIRA ART (Gen 2) system designed to elevate patient oxygen levels and potentially reduce the need for mechanical ventilation, providing new treatment alternatives and enhancing patient care.

08/10/2023 09:00 AM

News

Inspira™ Technologies Reports Second Quarter 2023 Financial Results

Rhea-AI Summary

Inspira Technologies OXY B.H.N. Ltd. announces financial results for Q2 2023. The company had $8.9 million in cash, cash equivalents, and short-term bank deposits as of June 30, 2023. The INSPIRA ART100 is planned for submission to the FDA for clearance. The INSPIRA ART500 is being developed with integrated AI and blood sensor technology. The net loss for the six months ended June 30, 2023, was $5.9 million.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

20%

Tags

08/09/2023 08:30 AM

News

INSPIRA™ ART100 Completes Usability Study in Boston Massachusetts, U.S.

Rhea-AI Summary

Inspira Technologies completes Usability Study for INSPIRA ART100 device

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

07/24/2023 09:17 AM

News

Inspira™ Technologies Receives Certification of Medical Devices Quality Management Systems, Another Step Towards EU Regulatory Approval

Rhea-AI Summary

Inspira Technologies has received ISO 13485:2016 Standard Certification, a requirement for EU regulatory approval. The certification demonstrates adherence to the highest quality management standards in the medical device industry.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-0.53%

Tags

07/19/2023 08:00 AM

News

Inspira™ Technologies Enters into Collaboration Agreement with U.S.-Based Perfusion Solution Inc.

Rhea-AI Summary

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

06/15/2023 09:30 AM

News

Inspira™ Technologies Unveils Investor Deck Showcasing Revolutionary Advancement in Acute Respiratory Care

Rhea-AI Summary

Inspira Technologies, a company aiming to revolutionize acute respiratory care, has released its latest investor deck. The deck highlights their vision, achievements, and projected targets for the second half of 2023. It showcases their cutting-edge extracorporeal blood circulation medical devices, including the INSPIRA™ ART500, which is designed to provide respiratory support without the need for mechanical ventilators. The deck also emphasizes the market potential of the company, with an estimated $20 billion total addressable market for their technologies.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

23.5%

Tags

05/30/2023 09:30 AM

News

Inspira Technologies Appoints Dr. Nir as Chief Medical Officer

Rhea-AI Summary

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-13.75%

Tags

05/18/2023 09:30 AM

News

Inspira™ Technologies Reports First Quarter 2023 Financial Results

Rhea-AI Summary

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-39.86%

Tags

05/16/2023 09:30 AM

News

Inspira™ Technologies will Reveal the New ALICE™ Device at the World's Largest Extracorporeal Life Support Conference

Rhea-AI Summary

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

05/11/2023 09:00 AM

News

Inspira™ Technologies is Developing the VORTX™ Blood Oxygenator, a Unique Technology for Saturating Blood With Oxygen and Removing Carbon Dioxide

Rhea-AI Summary

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

05/05/2023 09:00 AM

News

Inspira Technologies and Genius Group Interviews to Air on Bloomberg TV on the RedChip Money Report(R)

Rhea-AI Summary

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

Tags

FAQ

What is the current stock price of Inspira Technologies Oxy B.H.N. Ltd. Warrant (IINNW)?

The current stock price of Inspira Technologies Oxy B.H.N. Ltd. Warrant (IINNW) is $0.25 as of December 20, 2024.

What is Inspira Technologies Oxy BHN Ltd known for?

Inspira Technologies specializes in developing respiratory support technology as an alternative to mechanical ventilation.

What is the significance of OxyLink technology?

OxyLink is an advanced intravascular oxygenation apparatus that enhances blood oxygen levels and reduces carbon dioxide, facilitating effective treatment of ventilatory conditions.

What recent FDA clearance has Inspira Technologies received?

Inspira Technologies has received 510(k) class II clearance from the U.S. FDA for its INSPIRA ART100 Cardiopulmonary Bypass System.

How does the INSPIRA ART (Gen 2) system aim to revolutionize patient care?

The INSPIRA ART (Gen 2) system is designed to elevate patient oxygen levels, potentially reducing the need for mechanical ventilation and offering new treatment alternatives.

What is the core mission of Inspira Technologies?

Inspira Technologies aims to enhance patient care by developing innovative medical technologies that address critical respiratory needs and revolutionize the life support arena.